HatchMed wins marketing for ELUNATE® (fruquintinib)
— First drug approved under Hong Kong Special Administrative Region Government’s new ‘1+’ mechanism provides important treatment option for Hong Kong patients — — Erunate® This is the first oral targeted therapy approved for metastatic colorectal cancer in Hong Kong in nearly a decade, regardless of biomarker status or previous treatment. — Fruquintinib is already […]
Fruquintinib combination therapy improves quality-adjusted survival in metastatic colorectal cancer
3D illustration of the colon – Stock.adobe.com The combination of fruquintinib (Fruzakura) and optimal supportive care led to Results from an in-phase post-hoc analysis show that quality-adjusted time to absence of symptoms of disease or toxicity increased when compared with placebo and optimal supportive care in previously treated patients with metastatic colorectal cancer (CRC). The […]
Takeda receives FDA approval for fruquintinib for certain colorectal cancer patients
Photo: Takeda sign outside the California office/iStock; JHVE Photo The FDA on Wednesday approved Takeda Pharmaceutical’s fruquintinib for adult patients with previously treated metastatic colorectal cancer. Oral targeted therapy for VEGF-1, -2, and -3 receptors carries the brand name Furuzakura. Full Sakura-san label Patients previously treated with fluoropyrimidine, oxaliplatin, irinotecan chemotherapy, and anti-VEGF agents are […]
FDA approves fruquintinib for metastatic colorectal cancer
Approved by the US Food and Drug Administration fruquintinib (Furuzakura, Takeda) Treatment for certain metastatic adults colorectal cancer People who have experienced disease progression during or after previous treatment. More specifically, this approval also extends to adult patients with metastatic colorectal cancer who have previously received fluoropyrimidine, oxaliplatin, or irinotecan-based chemotherapy, anti-VEGF therapy, and in […]
FDA approves fruquintinib for metastatic colorectal cancer
The FDA has approved fruquintinib (Fluzacra) for the treatment of adult patients with metastatic colorectal cancer who were previously treated with fluoropyrimidine, oxaliplatin, irinotecan-based chemotherapy, or anti-VEGF therapy. R.A.S. Wild-type, medically relevant anti-EGFR therapy.1 This approval was based on results from the multiregional phase 3 FRESCO-2 trial (NCT04322539) and the Chinese phase 3 FRESCO trial […]
Japan seeks approval of fruquintinib for previously treated metastatic colorectal cancer
Colorectal cancer © Stock.adobe.com A new drug application (NDA) has been submitted to Japan’s Ministry of Health, Labor and Welfare seeking approval of fruquintinib (Elnato) for the treatment of adult patients with previously treated metastatic colorectal cancer (mCRC).1 The NDA is supported by data from the Phase 3 FRESCO-2 study (NCT04322539) and results from the […]